Johnson & Johnson's Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the … [Read More...] about European regulators offer positive opinion on Janssen’s schizophrenia treatment
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Navidea Biopharmaceuticals makes board of directors changes
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors. Dublin, Ohio–based Navidea 's chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from … [Read More...] about Navidea Biopharmaceuticals makes board of directors changes
European regulators offer positive opinion on Janssen’s schizophrenia treatment
Johnson & Johnson's Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the … [Read More...] about European regulators offer positive opinion on Janssen’s schizophrenia treatment
Alfred E. Mann Foundation sells insulin infusion pump IP to Medtronic
The Alfred E. Mann Foundation for Scientific Research (AMF) today announced the sale of intellectual property to Medtronic (NYSE:MDT). As part of the transaction of IP related to implanted infusion pumps, AMF will work with Medtronic to develop … [Read More...] about Alfred E. Mann Foundation sells insulin infusion pump IP to Medtronic
Diabeloop joins corporate advisory partnership, seeks to develop business in U.S.
Diabeloop announced today that it set up a local and dedicated team to support its pursuit of entry into the U.S. market. Paris-based Diabeloop develops an automated insulin delivery (AID) system that deployed throughout Europe this past year, … [Read More...] about Diabeloop joins corporate advisory partnership, seeks to develop business in U.S.
Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use … [Read More...] about Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
Philip Morris’ $1.2B offer for inhaled drug delivery tech developer becomes unconditional
Philip Morris (NYSE:PM) announced today that its offer to buy inhaled drug delivery technology developer Vectura has become unconditional. Having received valid acceptances for or acquired 74.77% of Vectura shares, in excess of the 50% required … [Read More...] about Philip Morris’ $1.2B offer for inhaled drug delivery tech developer becomes unconditional
Oramed hits 50% enrollment in Phase 2 trial for oral insulin capsule
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it reached over 50% enrollment in a trial for its oral insulin treatment. New York-based Oramed's Phase 2 trial evaluates its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic … [Read More...] about Oramed hits 50% enrollment in Phase 2 trial for oral insulin capsule
Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms. To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design … [Read More...] about Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax's offering includes 6.67 million shares of common stock priced at $6 per share, … [Read More...] about Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Gelteq wins U.S. patent for gel-based blood glucose testing platform
Gelteq announced today that it received a U.S. patent for its GTT Gel product for testing human response to oral glucose loads. Melbourne, Australia-based Gelteq designed its GTT Gel diabetes diagnostic system for use in pathology labs and at-home … [Read More...] about Gelteq wins U.S. patent for gel-based blood glucose testing platform
In case you missed it
- Lyra Therapeutics appoints new CFO
- Lyra touts non-human trial of XTreo drug-eluting implant
- Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment
- Dermavant doses first patient in trial of topical cream for atopic dermatitis
- Better Therapeutics expects $113M SPAC merger to go through in October
- MiMedx confirms shelf registration to sell $350M
- Sanofi to acquire Kadmon for $1.9B
- Eli Lilly to donate nearly $1M to Type 1 diabetes initiative
- AFYX touts trial of biodegradable drug delivery patch
- TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma
- FDA approves Impel NeuroPharma’s nasal spray for treating migraines
- Glaukos submits supplemental PMA application for iStent Infinite
- Fractyl activates 10th clinical site in diabetes reversal tech trial
- Overcoming vaccine delivery device design’s top challenges
- Baxter working on software upgrade for serious Spectrum IQ problems
Clinical Trials
European regulators offer positive opinion on Janssen’s schizophrenia treatment
Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. […]
Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of […]
Oramed hits 50% enrollment in Phase 2 trial for oral insulin capsule
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it reached over 50% enrollment in a trial for its oral insulin treatment. New York-based Oramed’s Phase 2 trial evaluates its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH), with patients continuing to be screened at sites in the U.S. and Israel, according to a news […]
Lyra touts non-human trial of XTreo drug-eluting implant
Lyra Therapeutics (NSDQ:LYRA) is touting preclinical data for its XTreo drug-eluting implant for dosing in local sinus tissues. Watertown, Massachusetts-based Lyra’s preclinical results were published — “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses” — were published online in the peer-review journal, American Journal of Rhinology & Allergy. The […]
Dermavant doses first patient in trial of topical cream for atopic dermatitis
Dermavant Sciences announced today that it dosed the first patient in a Phase 3 pivotal study of its atopic dermatitis (AD) treatment. Long Beach, California-based Dermavant’s double-blind, vehicle-controlled pivotal study evaluates tapinarof for the treatment of AD, according to a news release. The company developed tapinarof as an investigational novel, therapeutic aryl hydrocarbon receptor modulating […]
